The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Lymphocyte-to-monocyte ratio is a valuable marker to predict prostate cancer in patients with prostate specific antigen between 4 and 10 ng/dl
Abstract
Objective: To evaluate the diagnostic value of serum inflammation markers derived from complete blood count in diagnosis of prostate cancer (PCa). Methods: We retrospectively analyzed the data of 621 patients who underwent prostate biopsy between March 2013 and April 2018. Age, prostate specific antigen (PSA), free PSA, platelet count, neutrophil count, lymphocyte count, monocyte count, prostate volume (PV) and pathology result of the patients were recorded. Patients were grouped as benign prostatic hyperplasia (BPH), prostatitis and PCa. Patients were also grouped according to PSA values, as PSA < 4 , PSA 4-10 and PSA > 10 ng/dl. Results: The mean lymphocyte-to-monocyte ratio (LMR) value of the patients with PCa was significantly lower in the entire cohort (p = 0.047). In the PSA 4-10 ng/dl range, LMR value wassignificantly lower in patients with PCa than those with BPH or prostatitis (p = 0.012). In this PSA range, free/total PSA ratio and LMR were significant factors to predict PCa. The cut-off values of LMR, free/total PSA were 3.05 and 0.15 respectively. The sensitivities, spesificities, positive predictive values (PPV) and negative predictive values using LMR cut-off, free/total PSA cut-off and their combination were assessed. Specificity and PPV of the combination group were higher (97.2%, 83.3% respectively) compared to free/total PSA cut-off group (91.6%, 76.6%) and LMR cut-off group (67.8%, 43.7%).Conclusions: LMR is a useful tool at detecting PCa especially in patients with PSA value between 4 and 10 ng/dl. The combination of free/total PSA ratio and LMR improves the diagnostic accuracy more than the use of free/total PSA ratio alone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“higher LMRs are associated with better prognoses for a variety of leading sources of human mortality, including at least 8 types of cancer (e.g., prostate cancer; Caglayan et al., 2019), atherosclerosis (Gong et al., 2018), cardiovascular disease (Ji et al., 2017), and stroke (Ren, Liu, Wang, & Gao, 2017)]”
From Reversal of epigenetic aging and immunosenescent trends in humans. (2019) · cites this paper as Caglayan et al., 2019
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Templeton, A. J., McNamara, M. G., Šeruga, B., Vera-Badillo, F. E., Aneja, P., Ocaña, A., Leibowitz-Amit, R., Sonpavde, G., Knox, J. J., Tran, B., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju124 · Cited by 2,829
Heidenreich, A., Joaquim Bellmunt, B., Bolla, M., Joniau, S., Matveev, V. B., Mottet, N., Wiegel, T., & Zattoni, F. (2013) · Cited by 869
Templeton, A. J., Ace, O., McNamara, M. G., Al-Mubarak, M., Vera-Badillo, F. E., Hermanns, T., Šeruga, B., Ocaña, A., Tannock, I. F., & Amir, E. (2014) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-14-0146 · Cited by 719
Arnold, M., Karim-Kos, H. E., Coebergh, J. W., Byrnes, G., Antilla, A., Ferlay, J., Renehan, A. G., Forman, D., & Soerjomataram, I. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2013.09.002 · Cited by 513
Nishijima, T. F., Muss, H. B., Shachar, S. S., Tamura, K., & Takamatsu, Y. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.10.003 · Cited by 324
Neutrophil-to-lymphocyte ratio predicts prostatic carcinoma in men undergoing needle biopsy
Kawahara, T., Fukui, S., Sakamaki, K., Ito, Y., Ito, H., Kobayashi, N., Izumi, K., Yokomizo, Y., Miyoshi, Y., Makiyama, K., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5081 · Cited by 72
Ploussard, G., Nicolaı̈ew, N., Marchand, C., Terry, S., Allory, Y., Vacherot, F., Abbou, C.-C., Salomon, L., & TAILLE, A. D. L. (2013) · British Journal of Urology · doi:10.1111/j.1464-410x.2012.11607.x · Cited by 69
Prostate Specific Antigen as a Tumor Marker in Prostate Cancer: Biochemical and Clinical Aspects
Salman, J., Schoots, I. G., Carlsson, S., Jenster, G. W., & Roobol, M. J. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-94-017-7215-0_7 · Cited by 50
Nonsteroidal Anti-Inflammatory Drugs and Prostatic Diseases
Ishiguro, H., & Kawahara, T. (2014) · BioMed Research International · doi:10.1155/2014/436123 · Cited by 48
Research works printed but not linked: 2
- Gu X, Gao X, Li X, et al. Prognostic significance of neutrophil-to- lymphocyte ratio in prostate cancer: evidence from 16,266 patients. Sci Rep. 2016; 6:22089.
- Gokce MI, Hamidi N, Suer E, et al. Evaluation of neutrophil-to- lymphocyte ratio prior to prostate biopsy to predict biopsy histology: results of 1836 patients. Can Urol Assoc J. 2015; 9:E761-E765.
Cited by
Reversal of epigenetic aging and immunosenescent trends in humans.
Fahy, G. M., Brooke, R. T., Watson, J. P., Good, Z., Vasanawala, S. S., Maecker, H., Leipold, M. D., Lin, D. T. S., Kobor, M. S., & Horvath, S. (2019) · Aging Cell · doi:10.1111/acel.13028 · Cited by 477
Metadata
- Authors
- Caglayan, V., Onen, E., Avci, S., Sambel, M., Kilic, M., Oner, S., Aydos, M. M., & Yıldız, H. E.
- Venue
- Archivio Italiano di Urologia e Andrologia
- Publisher
- PAGEPress Publications
- Published
- 2019-01-17
- Volume
- 90
- Issue
- 4
- Pages
- 270-275
- ISSN
- 2282-4197
- 1124-3562
- Cited by
- 20
- References
- 18
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lymphocyte-to-monocyte ratio is a valuable marker to predict prostate cancer in patients with prostate specific antigen between 4 and 10 ng/dl. https://app.cochat.ai/papers/10.4081/aiua.2018.4.270
- The paper
- Caglayan, V., Onen, E., Avci, S., Sambel, M., Kilic, M., Oner, S., Aydos, M. M., & Yıldız, H. E. (2019). Lymphocyte-to-monocyte ratio is a valuable marker to predict prostate cancer in patients with prostate specific antigen between 4 and 10 ng/dl. Archivio Italiano di Urologia e Andrologia. https://doi.org/10.4081/aiua.2018.4.270
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
